𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The effect of intravenous zolendronic acid (ZOL) 5mgs once yearly in the treatment of postmenopausal osteoporosis. A peripheral quantitative computed tomography (PQCT) study

✍ Scribed by K. Stathopoulos; P. Katsimbri; E. Metania; E. Atsali; E. Eustathopoulos; A.B. Zoubos; G. Skarantavos

Book ID
116323442
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
71 KB
Volume
47
Category
Article
ISSN
8756-3282

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of a once-yearly i.v
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study
✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi